The Full Wiki

Shire plc: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Did you know ...

More interesting facts on Shire plc

Include this on your site/blog:


From Wikipedia, the free encyclopedia

Shire plc (formerly: Shire Pharmaceuticals Group Plc)
Founded 1986
Headquarters Registered Office: St Helier, Jersey
Corporate HQ: Dublin, Ireland
UK Operations: Basingstoke, England
Key people Matthew Emmens, Chairman
Angus Russell, CEO
Industry Pharmaceuticals
Revenue $3,007.7 million (2009)[1]
Operating income $620.2 million (2009)[1]
Net income $491.4 million (2009)[1]

Shire plc (LSE: SHP), (NASDAQSHPGY), (TSX:SHPGY-Q) is a Jersey registered, Irish head quartered manufacturer of pharmaceuticals.[2] Originating in and with a large operational base in the United Kingdom, its brands and products include Adderall XR, Carbatrol, Fosrenol, and the recently released Vyvanse.



Shire was founded by Harry Stratford following discussions with Dr James Murray in 1986.[3] It was first listed on the London Stock Exchange in 1996[3] and in 1997 it went on to acquire Pharmavene and Richmond Pharmaceutical Company.[3] In 2007 it acquired New River Pharmaceuticals Inc, a leading US drug maker, for $2.3bn.[4]


The Company seeks to develop and market products within advanced biotechnology for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

The Company focuses its drug research and development on the relatively common mental abnormality Attention Deficit Hyperactivity Disorder (ADHD), as is made evident by the fact that three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse), are intended for that disorder. However the Company also works on gastrointestinal (GI) treatments, human genetic therapies (HGT) and renal diseases.


A container of Adderall XR
Name Annual revenue[5] Indication
Adderall XR $1.1B Attention Deficit Hyperactivity Disorder (ADHD)
Vyvanse $318.9M Attention Deficit Hyperactivity Disorder (ADHD)
Elaprase $305.1M Hunter syndrome (lysosomal storage disorder)
Pentasa $185.5M Gastrointestinal (Ulcerative colitis)
Replagal $176.1M Fabry disease (lysosomal storage disorder)
Fosrenol $155.4M Renal disease
Lialda/Mezavant $140.4M Gastrointestinal (Ulcerative colitis)
Daytrana $78.7M Attention Deficit Hyperactivity Disorder (ADHD)
Xagrid (sold as Agrylin in the U.S.) $78.7M Essential thrombocytosis
Carbatrol $75.9M Epilepsy
Calcichew (UK) $52.8M Calcium supplements
Reminyl/Reminyl XL $34.4M Alzheimer's disease
Firazyr $0.5M Cardiovascular (Hereditary angioedema)

Royalty income

Name Annual revenue[6] Indication Licensee
3TC (Lamivudine) $140.2M HIV GlaxoSmithKline
Zeffix (Lamivudine) $40.3M Chronic hepatitis B GlaxoSmithKline


The original corporate head quarters and still major operation base are located in Basingstoke, Hampshire, England. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Owings Mills, Maryland.

In 2008, in reaction to new taxation measures announced by the Labour Party in the treatment of royalties on patents, the company moved its tax domicile to Dublin, Ireland.[7] Effected through the creation of a new holding company in St Helier, Jersey in the Channel Islands, it will pay reduced tax on global earnings, where royalties on patents lodged in Ireland are tax free.

Corporate leadership

The non-executive Board Chairman is Matthew Emmens. Angus Russell is the Chief Executive Officer. The President of the Human Genetic Therapies division is Sylvie Gregoire and Michael Cola is the President of Specialty Pharmaceuticals.


External links



Got something to say? Make a comment.
Your name
Your email address